Tempus to Present Six Abstracts Accepted at the 2026 Connective Tissue Oncology Society Annual Meeting
Tempus AI (TEM) Surged on Data Business Momentum and MRD Testing Expansion
SOTERIA Precision Medicine Foundation Partners With Tempus To Provide Personalized, Data-Driven Cancer Treatment Insights, Genomic Sequencing To U.S. Military
Tempus AI: Q3 Strengthens The Platform Thesis, But Cash Returns Still Need To Catch Up
Tempus AI: An Inflection Point Has Arrived (Earnings Analysis)
Jefferies Upgrades Tempus AI to Hold, Raises Price Target to $70
Freedom Capital Markets Maintains Hold on Tempus AI, Raises Price Target to $89
Tempus AI (TEM) Stock Looks Fully Priced Following Its 26% Run
HC Wainwright & Co. Maintains Buy on Tempus AI, Raises Price Target to $85
Tempus AI Analysts Boost Their Forecasts Following Strong Q3 Results
Baird Maintains Outperform on Tempus AI, Raises Price Target to $92
Cantor Fitzgerald Maintains Overweight on Tempus AI, Raises Price Target to $92
BTIG Maintains Buy on Tempus AI, Raises Price Target to $100
Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23% to $411. ...
Tempus AI, Inc. Q3 2026 Earnings Call Summary
Tempus AI Soars 10% on Q3 Beat and Raised Guidance as Oncology Sees “Accelerating Unit Growth”
Tempus (TEM) Q3 2026 Earnings Call Transcript
Tempus AI Revenue Up 23%; Gains Cut Net Loss: Rapid Earnings Reaction
Tempus AI shares jump as Q3 revenue beats expectations and company raises full-year outlook
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.